| Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion Y Hailemichael, Z Dai, N Jaffarzad, Y Ye, MA Medina, XF Huang, ... Nature medicine 19 (4), 465-472, 2013 | 507 | 2013 |
| Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice H Qin, B Lerman, I Sakamaki, G Wei, SC Cha, SS Rao, J Qian, ... Nature medicine 20 (6), 676-681, 2014 | 258 | 2014 |
| Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity Y Hailemichael, DH Johnson, N Abdel-Wahab, WC Foo, SE Bentebibel, ... Cancer Cell 40 (5), 509-523. e6, 2022 | 204 | 2022 |
| Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release P Jayaraman, F Parikh, E Lopez-Rivera, Y Hailemichael, A Clark, G Ma, ... The Journal of Immunology 188 (11), 5365-5376, 2012 | 179 | 2012 |
| Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy M Sharma, H Khong, F Fa’ak, SE Bentebibel, LME Janssen, BC Chesson, ... Nature communications 11 (1), 661, 2020 | 154 | 2020 |
| Targeted Inhibition of Inducible Nitric Oxide Synthase Inhibits Growth of Human Melanoma In vivo and Synergizes with Chemotherapy AG Sikora, A Gelbard, MA Davies, D Sano, S Ekmekcioglu, J Kwon, ... Clinical cancer research 16 (6), 1834-1844, 2010 | 149 | 2010 |
| IFN-α enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity AG Sikora, N Jaffarzad, Y Hailemichael, A Gelbard, SW Stonier, ... The Journal of Immunology 182 (12), 7398-7407, 2009 | 147 | 2009 |
| The glutaminase inhibitor CB-839 (telaglenastat) enhances the antimelanoma activity of T-cell–mediated immunotherapies S Varghese, S Pramanik, LJ Williams, HR Hodges, CW Hudgens, ... Molecular cancer therapeutics 20 (3), 500-511, 2021 | 102 | 2021 |
| Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain M Singh, C Vianden, MJ Cantwell, Z Dai, Z Xiao, M Sharma, H Khong, ... Nature communications 8 (1), 1447, 2017 | 95 | 2017 |
| Antitumor activity mediated by CpG: the route of administration is critical Y Lou, C Liu, G Lizée, W Peng, C Xu, Y Ye, BA Rabinovich, ... Journal of immunotherapy 34 (3), 279-288, 2011 | 87 | 2011 |
| Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy Y Hailemichael, A Woods, T Fu, Q He, MC Nielsen, F Hasan, J Roszik, ... The Journal of clinical investigation 128 (4), 1338-1354, 2018 | 86 | 2018 |
| Macrophages facilitate resistance to anti-VEGF therapy by altered VEGFR expression HJ Dalton, S Pradeep, M McGuire, Y Hailemichael, S Ma, Y Lyons, ... Clinical Cancer Research 23 (22), 7034-7046, 2017 | 86 | 2017 |
| Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma X Zhang, HC Lee, F Shirazi, V Baladandayuthapani, H Lin, I Kuiatse, ... Leukemia 32 (10), 2224-2239, 2018 | 84 | 2018 |
| Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter K Ritthipichai, CL Haymaker, M Martinez, A Aschenbrenner, X Yi, ... Clinical Cancer Research 23 (20), 6151-6164, 2017 | 64 | 2017 |
| Inhibition of p-STAT3 enhances IFN-α efficacy against metastatic melanoma in a murine model LY Kong, A Gelbard, J Wei, C Reina-Ortiz, Y Wang, EC Yang, ... Clinical Cancer Research 16 (9), 2550-2561, 2010 | 59 | 2010 |
| Soluble interleukin-15 complexes are generated in vivo by type I interferon dependent and independent pathways SM Anthony, ME Howard, Y Hailemichael, WW Overwijk, KS Schluns PLoS One 10 (3), e0120274, 2015 | 47 | 2015 |
| Host‐finding behavior, host acceptance, and host suitability of the parasite Xanthopimpla stemmator Y Hailemichael, JW Smith Jr, RN Wiedenmann Entomologia experimentalis et applicata 71 (2), 155-166, 1994 | 46 | 1994 |
| Peptide-based anticancer vaccines: The making and unmaking of a T-cell graveyard Y Hailemichael, WW Overwijk Oncoimmunology 2 (7), e24743, 2013 | 37 | 2013 |
| Mouse model for Pre‐Clinical study of human cancer immunotherapy Z Ya, Y Hailemichael, W Overwijk, NP Restifo Current protocols in immunology 108 (1), 20.1. 1-20.1. 43, 2015 | 35 | 2015 |
| Absence of Grail promotes CD8+ T cell anti-tumour activity C Haymaker, Y Yang, J Wang, Q Zou, A Sahoo, A Alekseev, D Singh, ... Nature communications 8 (1), 239, 2017 | 29 | 2017 |
